Adoption rates of immune checkpoint inhibitors in real world oncology practice.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e15103
Abstract: e15103Background: Inhibition of immune checkpoints such as PD-1, PD-L1, and CTLA-4, has become an important option in unleashing the immune system to fight cancer. However, there is limited informa... read more here.
Keywords: immune checkpoint; checkpoint inhibitors; rates immune; oncology ... See more keywords